Regeneron Pharmaceuticals, the $5.9 billion Tarrytown, N.Y.-based biotech firm, and gene therapy upstart Bluebird Bio will team up to invent genetically modified white blood cells that can attack cancer -- a technology known as CAR-T cells. The collaboration will make use of Regeneron's technologies for using mice to create human antibodies and receptors for T cells, a type of white blood cell.
https://www.forbes.com/sites/matthewherper/2018/08/06/regeneron-and-bluebird-team-invent-new-cell-therapies-for-cancer/
No comments:
Post a Comment